PUBLISHER: Grand View Research | PRODUCT CODE: 1529662
PUBLISHER: Grand View Research | PRODUCT CODE: 1529662
The U.S. ketamine clinics market size is anticipated to reach USD 6.90 billion by 2030, exhibiting a CAGR of 10.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the increase in mental health awareness, the ongoing opioid crisis, and an increasing number of ketamine clinics across the U.S. According to SAMHSA, in 2022, about 19.86% of adults, which is nearly 50 million people, had some form of mental illness, with 4.91% experiencing severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah.
Moreover, the COVID-19 pandemic had a negative impact on the mental health of adults, leading to an increased demand for innovative treatments. A survey by the Kaiser Family Foundation found that 39.3% of adults in the U.S. reported symptoms of anxiety or depressive disorder in February 2021, a significant increase from pre-pandemic levels. This increase in mental health issues has created the need for effective and rapid treatments, further driving the growth of the market in the U.S.
Moreover, the growing consolidation of local service providers with major ketamine clinic providers to offer ketamine treatments in the U.S. is expected to increase opportunities in the market. Market players are undertaking various strategic initiatives to increase their capabilities, improve competencies, and expand their service portfolios. For instance, in October 2023[, Nue Life Health was acquired by a venture studio specializing in psychedelic healthcare. This acquisition aligned with the studio's mission to advance innovative treatments in the mental wellness space, particularly through the use of psychedelic therapies.